Literature DB >> 24574405

Human herpesvirus 6A infection in CD46 transgenic mice: viral persistence in the brain and increased production of proinflammatory chemokines via Toll-like receptor 9.

Joséphine M Reynaud1, Jean-François Jégou, Jérémy C Welsch, Branka Horvat.   

Abstract

UNLABELLED: Human herpesvirus 6 (HHV-6) is widely spread in the human population and has been associated with several neuroinflammatory diseases, including multiple sclerosis. To develop a small-animal model of HHV-6 infection, we analyzed the susceptibility of several lines of transgenic mice expressing human CD46, identified as a receptor for HHV-6. We showed that HHV-6A (GS) infection results in the expression of viral transcripts in primary brain glial cultures from CD46-expressing mice, while HHV-6B (Z29) infection was inefficient. HHV-6A DNA persisted for up to 9 months in the brain of CD46-expressing mice but not in the nontransgenic littermates, whereas HHV-6B DNA levels decreased rapidly after infection in all mice. Persistence in the brain was observed with infectious but not heat-inactivated HHV-6A. Immunohistological studies revealed the presence of infiltrating lymphocytes in periventricular areas of the brain of HHV-6A-infected mice. Furthermore, HHV-6A stimulated the production of a panel of proinflammatory chemokines in primary brain glial cultures, including CCL2, CCL5, and CXCL10, and induced the expression of CCL5 in the brains of HHV-6A-infected mice. HHV-6A-induced production of chemokines in the primary glial cultures was dependent on the stimulation of toll-like receptor 9 (TLR9). Finally, HHV-6A induced signaling through human TLR9 as well, extending observations from the murine model to human infection. Altogether, this study presents a first murine model for HHV-6A-induced brain infection and suggests a role for TLR9 in the HHV-6A-initiated production of proinflammatory chemokines in the brain, opening novel perspectives for the study of virus-associated neuropathology. IMPORTANCE: HHV-6 infection has been related to neuroinflammatory diseases; however, the lack of a suitable small-animal infection model has considerably hampered further studies of HHV-6-induced neuropathogenesis. In this study, we have characterized a new model for HHV-6 infection in mice expressing the human CD46 protein. Infection of CD46 transgenic mice with HHV-6A resulted in long-term persistence of viral DNA in the brains of infected animals and was followed by lymphocyte infiltration and upregulation of the CCL5 chemokine in the absence of clinical signs of disease. The secretion of a panel of chemokines was increased after infection in primary murine brain glial cultures, and the HHV-6-induced chemokine expression was inhibited when TLR9 signaling was blocked. These results describe the first murine model for HHV-6A-induced brain infection and suggest the importance of the TLR9 pathway in HHV-6A-initiated neuroinflammation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24574405      PMCID: PMC4019085          DOI: 10.1128/JVI.03763-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  84 in total

1.  Polymorphic expression of CD46 protein isoforms due to tissue-specific RNA splicing.

Authors:  R W Johnstone; S M Russell; B E Loveland; I F McKenzie
Journal:  Mol Immunol       Date:  1993-10       Impact factor: 4.407

2.  Identification and quantification of complement regulator CD46 on normal human tissues.

Authors:  R W Johnstone; B E Loveland; I F McKenzie
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

3.  Human herpesvirus 6 infection in normal human brain tissue.

Authors:  M Luppi; P Barozzi; A Maiorana; R Marasca; G Torelli
Journal:  J Infect Dis       Date:  1994-04       Impact factor: 5.226

4.  The human CD46 molecule is a receptor for measles virus (Edmonston strain).

Authors:  R E Dörig; A Marcil; A Chopra; C D Richardson
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

5.  Efficient MHC class II-restricted presentation of measles virus to T cells relies on its targeting to its cellular receptor human CD46 and involves an endosomal pathway.

Authors:  D Gerlier; M C Trescol-Biémont; G Varior-Krishnan; D Naniche; I Fugier-Vivier; C Rabourdin-Combe
Journal:  Cell Biol Int       Date:  1994-05       Impact factor: 3.612

6.  Experimental infection of cynomolgus and African green monkeys with human herpesvirus 6.

Authors:  S Yalcin; T Mukai; K Kondo; Y Ami; T Okawa; A Kojima; T Kurata; K Yamanishi
Journal:  J Gen Virol       Date:  1992-07       Impact factor: 3.891

7.  Immunosuppressive effect of human herpesvirus 6 on T-cell functions: suppression of interleukin-2 synthesis and cell proliferation.

Authors:  L Flamand; J Gosselin; I Stefanescu; D Ablashi; J Menezes
Journal:  Blood       Date:  1995-03-01       Impact factor: 22.113

8.  Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus.

Authors:  D Naniche; G Varior-Krishnan; F Cervoni; T F Wild; B Rossi; C Rabourdin-Combe; D Gerlier
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  Plaque-associated expression of human herpesvirus 6 in multiple sclerosis.

Authors:  P B Challoner; K T Smith; J D Parker; D L MacLeod; S N Coulter; T M Rose; E R Schultz; J L Bennett; R L Garber; M Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

10.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

View more
  28 in total

Review 1.  Roseolovirus molecular biology: recent advances.

Authors:  Laurie T Krug; Philip E Pellett
Journal:  Curr Opin Virol       Date:  2014-11-27       Impact factor: 7.090

2.  Cell Culture Systems To Study Human Herpesvirus 6A/B Chromosomal Integration.

Authors:  Annie Gravel; Isabelle Dubuc; Nina Wallaschek; Shella Gilbert-Girard; Vanessa Collin; Ruth Hall-Sedlak; Keith R Jerome; Yasuko Mori; Julie Carbonneau; Guy Boivin; Benedikt B Kaufer; Louis Flamand
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

3.  A Murine Herpesvirus Closely Related to Ubiquitous Human Herpesviruses Causes T-Cell Depletion.

Authors:  Swapneel J Patel; Guoyan Zhao; Vinay R Penna; Eugene Park; Elvin J Lauron; Ian B Harvey; Wandy L Beatty; Beatrice Plougastel-Douglas; Jennifer Poursine-Laurent; Daved H Fremont; David Wang; Wayne M Yokoyama
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

Review 4.  Recent developments in animal models for human herpesvirus 6A and 6B.

Authors:  Branka Horvat; Bradford K Berges; Paolo Lusso
Journal:  Curr Opin Virol       Date:  2014-10-14       Impact factor: 7.090

5.  Determinants of Human CD134 Essential for Entry of Human Herpesvirus 6B.

Authors:  Huamin Tang; Yasuko Mori
Journal:  J Virol       Date:  2015-07-22       Impact factor: 5.103

6.  CD46 Isoforms Influence the Mode of Entry by Human Herpesvirus 6A/B in T Cells.

Authors:  Litten Sørensen Rossen; Vivien R Schack; Katrine Kyd Holstein Thuesen; Bettina Bundgaard; Per Höllsberg
Journal:  J Virol       Date:  2022-01-12       Impact factor: 6.549

Review 7.  Laboratory and clinical aspects of human herpesvirus 6 infections.

Authors:  Henri Agut; Pascale Bonnafous; Agnès Gautheret-Dejean
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 8.  Serological evidence that activation of ubiquitous human herpesvirus-6 (HHV-6) plays a role in chronic idiopathic/spontaneous urticaria (CIU).

Authors:  D H Dreyfus
Journal:  Clin Exp Immunol       Date:  2015-11-24       Impact factor: 4.330

Review 9.  Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation.

Authors:  Anthony L Komaroff; Philip E Pellett; Steven Jacobson
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

10.  Evaluation of a method to measure HHV-6B infection in vitro based on cell size.

Authors:  Aniuska Becerra-Artiles; Tessa Santoro; Lawrence J Stern
Journal:  Virol J       Date:  2018-01-05       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.